Kornimate/medical-research-clean huggingface dataset:
a randomized study to compare a hydrogel packing system to standard packing during hdr brachytherapy for cervical cancer

Conditions: Cervical Cancer

Summary: in this study, a new, low cost packing system ("brachygel vhps") is being tested as a packing option during brachytherapy along with standard options to make sure that it keeps the unrelated organs away from radiation at least as well as the standard options, and to better understand the safety and patient discomfort associated with brachygel vhps and the standard packing options.

as part of vaginal brachytherapy, the organs that do not need to receive radiation (unrelated organs) are moved out of the way of the radiation with a "packing system". the usual low cost and available standard of care packing systems to move these unrelated organs out of the way can sometimes be uncomfortable for the patient, may not move all of the unrelated organs all the way out of the radiation's path, and rely on the doctor to place them correctly. if you participate, you will receive 5 fractions of brachytherapy according to standard clinical care. for three of the fractions, a standard packing option will be used and for two of them brachygel vhps will be used. for the first fraction both groups will have the same packing option but participants will be randomized to either have brachygel during fractions 2 and 4 or during fractions 3 and 5. you'll be asked to complete a questionnaire after fractions 2-5 to get your feedback on any discomfort you have during or after brachytherapy from the packing system.

Eligibility criteria:
inclusion criteria: 1. biopsy showing cancer of the cervix (squamous cell carcinoma, adenocarcinoma, adenosquamous, neuroendocrine, etc) 2. figo ib1 - ivb staging according to figo and tnm guidelines 3. planning to receive brachytherapy as a part of the definitive treatment for cervical cancer 4. karnofsky performance status (kps) ≥ 70 or ecog status ≤1 5. stated willingness to comply with all study procedures and availability for the duration of the study 6. age ≥ 18 years 7. agreement to adhere to lifestyle considerations throughout study duration exclusion criteria: 1. history of pelvis or abdominal radiation therapy (rt) that is not a part of the definitive treatment plan for the cancer of interest" 2. history of total or partial hysterectomy 3. plan to receive external beam rt (ebrt) alone as the definitive treatment plan for the cancer of interest 4. known pregnancy or lactation (no pregnancy test required prior to participation) 5. known contraindications to brachytherapy

Keywords: brachytherapy
efficacy of double contrast-enhanced ultrasound of pelvic in preoperative evaluation of deep endometriosis

Conditions: Deep Endometriosis

Summary: endometriosis occurs in about 10-15% of women of childbearing age and is a major cause of infertility and dysmenorrhea. deep endometriosis is the most serious manifestation of endometriosis, which often affects the quality of life of patients and requires surgical treatment. detailed description of de lesions before operation can contribute to treatment planning. however, the detection rate of de by conventional ultrasound is low, highly dependent on the experience of the examiner and poor reproducibility. hysterosalpingo-contrast sonography can be used to assess the patency of the fallopian tube but cannot visualize other pelvic structures. saline-infusion sonopodography can provide a good acoustic window for pelvic tissue visualization. therefore, this study is the first to present double contrast-enhanced ultrasound (hysterosalpingo-contrast sonography and sonopodography) examination of the pelvic cavity, based on the #enzian classification system, for preoperative evaluation of de lesions. the results of laparoscopic surgery were taken as the gold standard to compare the diagnostic efficacy of double contrast-enhanced ultrasound and conventional transvaginal ultrasound in preoperative evaluation of pelvic de lesions, improving the preoperative diagnosis, reduce the risk of surgery and reduce postoperative recurrence. to compare the diagnostic efficacy of different examination methods in different compartment of de, and to explore the best examination method suitable for different parts of de, providing theoretical basis for further early screening and personalized treatment of de in the future.


Eligibility criteria:
inclusion criteria: 1. female patients diagnosed with adenomyosis and/or chocolate cysts, suspected infertility with endometriosis, and proposed for laparoscopic surgery at our hospital. 2. sexual life history. 3. surgery was performed within 2 months of the examination. 4. subjects volunteered to participate in the study and signed the informed consent form. exclusion criteria: 1. colporrhagia. 2. acute inflammation of reproductive system. 3. allergic to ultrasound contrast agent (sonovue). 4. suspected malignant lesions of cervix or uterine cavity.

Keywords: deep endometriosis contrast-enhanced ultrasound #enzian classification preoperative evaluation
real evidence of anticoagulation treatment in non-valvular atrial fibrillation in germany, uk and france: react-af2

Conditions: Non-valvular Atrial Fibrillation

Summary: the purpose of this study is to determine and compare the persistence rate of newly prescribed apixaban, rivaroxaban, dabigatran and vkas in patients with nvaf.

actual number of patients enrolled for uk : 15242 patients actual number of patients enrolled for germany : 22880 patients

Eligibility criteria:
inclusion criteria: * have an apixaban, rivaroxaban, dabigatran or vka prescription during the study period * are ≥18 years old at index date * have ≥12 months of computerised medical data prior to index date * have a record of af on or ever prior to index date (index oac prescription) exclusion criteria: * have a record for a valvular condition (ie, rheumatic valvular disease and prosthetic valves) on or ever prior to index date * have a history (ever prior to index date) of the oral anticoagulant (oacs) which are prescribed during the study period
safety and immune response of novartis of menacwy conjugate vaccine when given to healthy children

Conditions: Meningococcal Infections

Summary: to evaluate the safety and immune response of novartis menacwy conjugate vaccine when given to healthy children compared to a licensed meningococcal acwy polysaccharide-protein conjugate vaccine.


Eligibility criteria:
inclusion criteria: * healthy 2-10 years of age children, inclusive and for whom, after the nature of the study has been explained, the parent or legal guardian has provided written informed consent * who are available for all visits and telephone calls scheduled for the study * who are up-to-date with age-appropriate routine childhood vaccinations exclusion criteria: * whose parent or legal guardian is unwilling or unable to give written informed consent * who had a previous or suspected disease caused by n. meningitidis; * who have previously been immunized with a meningococcal vaccine or vaccine containing meningococcal antigen(s) * who have received any investigational agents or vaccines within 90 days prior to enrollment * who have any serious acute, chronic or progressive disease * who have epilepsy or any progressive neurological disease or history of guillain barré syndrome * who have a history of anaphylaxis, serious vaccine reactions * who have a known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from * who are known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time * who have down's syndrome or other known cytogenic disorders

Keywords: vaccine children healthy meningitis meningococcal prevention of meningococcal disease serogroups acwy menveo
acupuncture in depression: from the clinical trial, biomarkers to molecular biology

Conditions: Major Depressive Disorder

Summary: major depressive disorder (mdd) is a serious psychiatric illness with a high lifetime prevalence rate and causes major clinical, social and economic burden to patients and their family. despite more than 40 antidepressants with various mechanisms are available on the market, half of patients fail to achieve remission with optimized medication treatment. due to unsatisfactory efficacy, frequent intolerability and poor compliance of psychopharmacotherapies, novel and safe alternative therapies are critically in need to improve the treatment of depression. traditional chinese medicine (tcm) theory describes a state of health maintained by a balance of energy in the body. if imbalanced, it can be corrected by acupuncture, the insertion of fine needles into different parts of the body. although there are several clinical trials to demonstrate the antidepressant effects of acupuncture, its biological and physiological mechanisms are still unknown. in addition, clinical depression is frequently accompanied with somatic presentations, which are related to autonomic nervous dysfunction. it would be of interest to know if acupuncture could regulate autonomic nervous system (ans) and improve the somatic symptoms in depression. the purpose of this study is to assess the effectiveness of acupuncture in the treatment of depression and to determine the influence of acupuncture on the molecular and ans systems.

in this study,the investigators will test the antidepressant effect of acupuncture versus sham intervention on major depression, in an eight-week, double-blind, randomized-controlled trial in 40 mdd patients who still have significant depressive symptoms without changing at their treatment modality for the last 4 weeks. during the visits at weeks 0 (baseline), 1, 2, 4, 6, 8 (intervention), and 12 (4 weeks after intervention), subjects will be assessed depressive symptoms with the 21-item hamilton rating scale for depression (ham-d). before and after the intervention (weeks 0 and 8),computerized tcm constitution diagnosis will be measured and the blood samples will be collected for biomarker analyses, including neurotransmitter, inflammatory molecules and immunologic function. all parts of this research will start after being approved by the institution review board in study sites. the outcomes of this study could provide the evidence of applying acupuncture as an alternative effective treatment for depression and to improve the understanding of biological mechanisms for its antidepressant effects.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of major depressive disorder (mdd) * over 18 on the 21-item hamilton rating scale for depression exclusion criteria: * schizophrenia * ubstance dependence disorders

Keywords: acupuncture traditional chinese medicine major depressive disorder
acute effects of cryotherapy duration in healthy individuals

Conditions: Cryotherapy Effect

Summary: the study will investigate the acute effects of cryotherapy duration on shoulder muscle strength, flexibility, endurance and dynamic balance in healthy individuals.

cryotherapy is a practice that induces therapeutic effects by reducing tissue temperature to produce an analgesic effect. cryotherapy application methods vary from simple ice packs and cold water immersion to whole body cryotherapy methods. the purpose of cryotherapy treatment is to reduce tissue damage, muscle spasm, edema and pain and to provide a faster rehabilitation process after injury. it is also used as a recovery technique after high-intensity training in different sports branches. despite the proven benefits of cryotherapy according to the literature, discussions continue about its effect on some parameters and there is no consensus on the duration of cryotherapy application. in addition, although there are studies on the effects of cryotherapy on the lower extremities, studies for the upper extremity are limited and the results of these studies are inconsistent. in the literature, no study was found that evaluated the effect of cryotherapy application time on shoulder muscle strength, endurance, flexibility and balance. therefore, in this study, the acute effects of cryotherapy duration on shoulder muscle strength, flexibility, endurance and dynamic balance in healthy individuals will be investigated and the optimum duration of cryotherapy on these parameters will be determined. in addition, the results of the research will contribute to the planned rehabilitation and exercise program.

Eligibility criteria:
inclusion criteria: * individuals between the ages of 18-25 who volunteer to participate in the study * no upper extremity orthopedic problems * no history of shoulder injury or surgery in the past two years * absence of raynaud's disease or cold intolerance exclusion criteria: * having a history of shoulder injury or surgery * cervical or thoracic spine disorders * people with any neurological disorder or known balance/proprioceptive deficits * decreased sensation or decreased blood flow * have raynaud's disease or any cold intolerance

Keywords: cryotherapy muscle strength flexibility endurance balance healthy people cold pack shoulder
primary progressive aphasia multicomponent language treatment study

Conditions: Primary Progressive Aphasia; Semantic Dementia; Semantic Memory Disorder; Logopenic Progressive Aphasia; Nonfluent Aphasia, Progressive; Aphasia; Aphasia, Progressive

Summary: primary progressive aphasia (ppa) is a progressive neurological disorder that causes a gradual decline in communication ability as a result of selective neurodegeneration of speech and language networks in the brain. ppa is a devastating condition affecting adults as young as in their 50's, depriving them of the ability to communicate and function in society. as a result of improved diagnostic precision, ppa is now identified with greater accuracy and frequency and, increasingly, patients and their families seek options for behavioral treatments to ameliorate the devastating effects on their communication, prolong speech language skills, and maximize quality of life. speech-language treatment outcomes from our group and others are encouraging, confirming that behavioral intervention may lead to improvements in trained behaviors and, for some interventions, lasting and generalized benefit. most speech-language interventions for individuals with ppa that have been explored in the literature are restitutive, or impairment-based in nature, and have not addressed the full range of severity and phenotypic variability in this population. the investigators will evaluate the utility of a novel, multicomponent intervention that incorporates elements of restitutive (e.g., word finding strategic training, script training), compensatory (e.g., multimodal communication, communication book), and care partner-focused treatment to meet the needs of individuals varying in clinical presentation and severity.


Eligibility criteria:
inclusion criteria: * meets diagnostic criteria for primary progressive aphasia (ppa; gorno-tempini et al., 2011) * scores of 10 or higher on the mini-mental state examination * has a study partner who can consistently attend sessions exclusion criteria: * other neurological or psychiatric diagnosis that may contribute to cognitive-linguistic deficits * significant, uncorrected visual or hearing impairment that would interfere with participation * score of less than 10 on the mini-mental state examination * prominent initial non-speech-language impairment (cognitive, behavioral, motoric)

Keywords: speech-language pathology neurodegenerative disease logopenic semantic nonfluent speech entrainment telethearpy multimodal communication training partner training augmentative and alternative communication script training
study to evaluate the safety, pharmacokinetics and clinical activity of rp7214 in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia

Conditions: Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Acute Myeloid Leukemia

Summary: this is a multi-center, open-label, non-randomized, two-part phase i/ib study of rp7214 in combination with azacitidine in patients with aml, mds and cmml. part i is a 3+3 dose-escalation study to identify the mtd/rp2d of rp7214 and azacitidine combination in patients with aml, mds, and cmml. part ii is a dose-expansion study to evaluate the clinical activity and safety of rp7214 and azacitidine combination in aml.


Eligibility criteria:
inclusion criteria: 1. patient must sign informed consent. 2. patient should be ≥ 18 years of age. 3. patients who are candidates for treatment with azacitidine and present with one of the following: a. part i: dose escalation study i. patient with histologically or cytologically confirmed relapsed/refractory aml as per world health organization (who) classification, 2016 'or' ii. newly diagnosed aml patients who are ineligible for intensive induction chemotherapy due to co-morbidity or other factors 'or' iii. intermediate-2 or high-risk mds according to the international prognostic scoring system (ipss) 'or' iv. chronic myelomonocytic leukemia (cmml) b. part ii: dose expansion study i. newly diagnosed aml patients who are ineligible for intensive induction chemotherapy due to co-morbidity or other factors. 4. patient should have an eastern cooperative oncology group (ecog) performance score of 0 to 2. 5. patients must be amenable to serial bone marrow biopsies/aspirates and peripheral blood sampling as required by the protocol. exclusion criteria: 1. any cancer-directed therapy taken (e.g., chemotherapy, immunotherapy, biologic therapy or an investigational drug) within 14 days or 5 half-lives, whichever is shorter, prior to c1d1. for radiation therapy, at least 60 days should elapse from prior total body irradiation (tbi) and at least 14 days from local palliative radiation therapy. 2. patients with rapidly increasing peripheral blast counts (wbc count \> 25,000/μl) while on hydroxyurea prior to c1d1. 3. patients with acute promyelocytic leukemia (french american-british class m3 aml). 4. patients on immunosuppressive therapy post autologous or allogeneic stem cell transplantation (asct or allo-sct) at the time of screening, or with clinically significant graft-versus-host disease (gvhd) in the opinion of the investigator or has not recovered from transplant-associated toxicities prior to c1d1. 5. patient who discontinued prior therapy with dhodh inhibitors or azacitidine due to drug-related toxicity. 6. evidence of uncontrolled/progressing infection. 7. patients with immediate life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation (dic). 8. presence of isolated extramedullary relapse. 9. pregnant or lactating women

Keywords: rp7214 dihydro-orotate dehydrogenase (dhodh)
chemotherapy and proton radiation for the treatment of locally advanced lung cancer

Conditions: Locally Advanced Non-Small Cell Lung Cancer

Summary: the purpose of this study is to determine the effectiveness of proton beam radiotherapy combined with chemotherapy for treatment of locally advanced non-small cell lung cancer.


Eligibility criteria:
inclusion criteria: * clinical stage 2, 3a or 3b (unresectable) * histologic evidence of non-small cell carcinoma * age \> 18 years * karnofsky performance status 70 or greater * no prior radiation to the chest * no previous chemotherapy exclusion criteria: * clinical stage 1 or 4 * previous malignancies except for non-melanoma skin cancer unless disease free for \> 3 years

Keywords: proton radiation
impact of covid 19 on psoriasis patients

Conditions: The Impact of COVID19 on Psoriasis Patients

Summary: the main objective of this work is to investigate the effect of covid-19 pandemic on psoriasis patients. this work is designed as a cross-sectional survey based on a questionnaire directed to egyptian psoriasis patients.


Eligibility criteria:
inclusion criteria: * psoriaisis patients exclusion criteria: * children
tocotrienols for school-going children with adhd

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: the purpose of this study is to determine if tocotrienol supplementation given to school going children with adhd will result in reduction of their adhd symptoms.

the main objective of the study is to: a. determine if supplementation of tocotrienol compared to placebo has an effect on the symptoms of school going children with adhd. the secondary objective is to: 1. determine if supplementation of tocotrienol compared to placebo has an effect on the dose of current medication used in school going children with adhd. 2. determine the safety of tocotrienol in the study population. 3. determine if tocotrienol levels in children with adhd correlate with their symptom scores.

Eligibility criteria:
inclusion criteria: * diagnosed with adhd in accordance with the diagnostic and statistical manual (dsm) iv criteria. * be able to swallow soft gel capsules. * if already on medication for adhd, the dose of the medication must be stable for the last 3months * be able to attend all follow up visits. * be agreeable to have their teacher score the national initiative for children's healthcare quality (nichq) vanderbilt assessment scale - teacher informant * be willing to have their blood taken 3 times during the study. exclusion criteria: * adhd caused by syndromes, inborn errors of metabolism, or structural brain lesions. * co-existing chronic liver disease * current use of anticoagulant or antiplatelet drugs.

Keywords: adhd children tocotrienol